| Autor: |
Adikwu, Elias, Igono, Simeon Ajeka, Ebong, Nwakaego Omonigho |
| Předmět: |
|
| Zdroj: |
American Journal of Biomedical Sciences; Jan2022, Vol. 14 Issue 1, p29-38, 10p |
| Abstrakt: |
Objective: The concurrent use of antibiotics and antimalarial drugs may increase Plasmodium susceptibility. Clindamycin (C) is an antibiotic with potential antiplasmodial activity. Dihydroartemisininpiperaquine (D-P) is an effective antimalarial drug. This study examined the antiplasmodial effect of dihydroartemisinin-piperaquine-clindamycin (D-P-C) on mice infected with Plasmodium berghei. Methods: Adult Swiss albino mice (25-30g) of n=6/group were used. Using the curative, suppressive and prophylactic tests, mice were infected with Plasmodium. berghei and orally treated per day with D-P (1.71/13.7mg/kg), C (10mg/kg) and D-P-C, respectively. The positive control was orally treated per day with chloroquine (CQ) (10 mg/kg) whereas the normal and the negative controls were orally treated per day with normal saline (0.2ml). Results: In the curative, suppressive and prophylactic tests, D-P-C decreased percentage parasitemia levels with significant difference observed at p<0.05 when compared to individual doses of C, D-P and CQ. D-P-C significantly prolonged mean survival time with difference observed at p< 0.05 when compared to individual doses of D and D-P. The anti-anemic effect of D-P-C was characterized by increased hemoglobin, red blood cells, packed cell volume and decreased white blood cells with significant difference observed at p<0.05 when compared to individual doses of C, D-P and CQ. Treatment with D-P-C eradicated liver Plasmodium. Conclusion: D-P-C showed promising antiplasmodial activity. It may be used for the treatment of malaria. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
